Grading of neuropathology in multiple system atrophy : Proposal for a novel scale
Identifieur interne :
000F45 ( PascalFrancis/Curation );
précédent :
000F44;
suivant :
000F46
Grading of neuropathology in multiple system atrophy : Proposal for a novel scale
Auteurs : Kurt A. Jellinger [
Autriche] ;
Klaus Seppi [
Autriche] ;
Gregor K. Wenning [
Autriche]
Source :
-
Movement disorders [ 0885-3185 ] ; 2005.
RBID : Pascal:05-0457530
Descripteurs français
English descriptors
Abstract
Multiple system atrophy (MSA), a sporadic progressive synucleinopathy of advanced age, is separated into two clinic opathological subtypes: MSA-P (striatonigral degeneration [SND]) with predominant parkinsonian features and MSA-C (olivopontocerebellar atrophy [OPCA]) with predominant cerebellar ataxia. We propose a novel morphological grading system for both subtypes to compare lesion intensities and their possible clinical validity. Forty-two autopsy cases of MSA were separated into four grades (SND 0-III and OPCA 0-III) based on semiquantitative assessment of neuronal loss, astrogliosis, and presence of α-synuclein-positive glial cytoplasmic inclusions (GCI) in striatum, globus pallidus, substantia nigra, pontine basis, cerebellum, and inferior olives. Whereas a recent grading system restricted to SND reflected disease progression and dopa-responsiveness, there was considerable variation in the morphological combination between SND and OPCA, with only around half the cases with OPCA II (moderate) and III (severe) showing comparable grades of both types, whereas OPCA 0 and I (no or little degeneration) was combined with all grades of SND. Twenty-two cases showing OPCA 0 + SND II (n = 3), OPCA I + SND I-II (n = 11), and OPCA I + SND III (n = 8) were classified as pure or predominant SND, consistent with MSA-P. Twenty cases showing OPCA II + SND II/III (n = 7) and OPCA III + SND III (n = 13) were classified as predominant OPCA, consistent with MSA-C. In MSA-P, the mean age of onset was higher than it was in MSA-C (55.1 vs. 50.5 years), but the mean duration of illness was shorter in MSA-P (5.3 vs. 6.7 years). Presenting symptoms in MSA-P were mainly parkinsonism, whereas in MSA-C they were mainly gait disorders (14 vs. 1; P < 0.001). Among clinical key symptoms, parkinsonism was more frequent than were cerebellar signs in MSA-P; in MSA-C it was the reverse (P < 0.01), whereas other symptoms (autonomic/ urinary failure) showed no differences. Parkinsonism was infrequent in MSA-C even when OPCA was associated with SND, suggesting a masking effect by cerebellar system involvement. High terminal Hoehn and Yahr stages were more frequent in MSA-P (P < 0.01), some with good-to-moderate initial levodopa (L-dopa) response. Although the proposed morphological grading of both MSA-P and -C correlates well with initial symptoms and clinical key features of both types, further prospective studies are required to validate the clinical utility of the proposed MSA grading scales for future intervention studies.
| pA |
| A01 | 01 | 1 | | @0 0885-3185 |
|---|
| A03 | | 1 | | @0 Mov. disord. |
|---|
| A05 | | | | @2 20 |
|---|
| A06 | | | | @3 SUP12 |
|---|
| A08 | 01 | 1 | ENG | @1 Grading of neuropathology in multiple system atrophy : Proposal for a novel scale |
|---|
| A09 | 01 | 1 | ENG | @1 Atypical Parkinsonian Disorders |
|---|
| A11 | 01 | 1 | | @1 JELLINGER (Kurt A.) |
|---|
| A11 | 02 | 1 | | @1 SEPPI (Klaus) |
|---|
| A11 | 03 | 1 | | @1 WENNING (Gregor K.) |
|---|
| A12 | 01 | 1 | | @1 POEWE (Werner) @9 ed. |
|---|
| A12 | 02 | 1 | | @1 WENNING (Gregor K.) @9 ed. |
|---|
| A14 | 01 | | | @1 Institute of Clinical Neurobiology @2 Vienna @3 AUT @Z 1 aut. |
|---|
| A14 | 02 | | | @1 Department of Neurology, University of Innsbruck School of Medicine @2 Innsbruck @3 AUT @Z 2 aut. @Z 3 aut. |
|---|
| A15 | 01 | | | @1 Department of Neurology, Medical University Innsbruck @2 Innsbruck @3 AUT @Z 1 aut. @Z 2 aut. |
|---|
| A20 | | | | @2 S29-S36 |
|---|
| A21 | | | | @1 2005 |
|---|
| A23 | 01 | | | @0 ENG |
|---|
| A43 | 01 | | | @1 INIST @2 20953 @5 354000132714250050 |
|---|
| A44 | | | | @0 0000 @1 © 2005 INIST-CNRS. All rights reserved. |
|---|
| A45 | | | | @0 28 ref. |
|---|
| A47 | 01 | 1 | | @0 05-0457530 |
|---|
| A60 | | | | @1 P @2 C |
|---|
| A61 | | | | @0 A |
|---|
| A64 | 01 | 1 | | @0 Movement disorders |
|---|
| A66 | 01 | | | @0 USA |
|---|
| C01 | 01 | | ENG | @0 Multiple system atrophy (MSA), a sporadic progressive synucleinopathy of advanced age, is separated into two clinic opathological subtypes: MSA-P (striatonigral degeneration [SND]) with predominant parkinsonian features and MSA-C (olivopontocerebellar atrophy [OPCA]) with predominant cerebellar ataxia. We propose a novel morphological grading system for both subtypes to compare lesion intensities and their possible clinical validity. Forty-two autopsy cases of MSA were separated into four grades (SND 0-III and OPCA 0-III) based on semiquantitative assessment of neuronal loss, astrogliosis, and presence of α-synuclein-positive glial cytoplasmic inclusions (GCI) in striatum, globus pallidus, substantia nigra, pontine basis, cerebellum, and inferior olives. Whereas a recent grading system restricted to SND reflected disease progression and dopa-responsiveness, there was considerable variation in the morphological combination between SND and OPCA, with only around half the cases with OPCA II (moderate) and III (severe) showing comparable grades of both types, whereas OPCA 0 and I (no or little degeneration) was combined with all grades of SND. Twenty-two cases showing OPCA 0 + SND II (n = 3), OPCA I + SND I-II (n = 11), and OPCA I + SND III (n = 8) were classified as pure or predominant SND, consistent with MSA-P. Twenty cases showing OPCA II + SND II/III (n = 7) and OPCA III + SND III (n = 13) were classified as predominant OPCA, consistent with MSA-C. In MSA-P, the mean age of onset was higher than it was in MSA-C (55.1 vs. 50.5 years), but the mean duration of illness was shorter in MSA-P (5.3 vs. 6.7 years). Presenting symptoms in MSA-P were mainly parkinsonism, whereas in MSA-C they were mainly gait disorders (14 vs. 1; P < 0.001). Among clinical key symptoms, parkinsonism was more frequent than were cerebellar signs in MSA-P; in MSA-C it was the reverse (P < 0.01), whereas other symptoms (autonomic/ urinary failure) showed no differences. Parkinsonism was infrequent in MSA-C even when OPCA was associated with SND, suggesting a masking effect by cerebellar system involvement. High terminal Hoehn and Yahr stages were more frequent in MSA-P (P < 0.01), some with good-to-moderate initial levodopa (L-dopa) response. Although the proposed morphological grading of both MSA-P and -C correlates well with initial symptoms and clinical key features of both types, further prospective studies are required to validate the clinical utility of the proposed MSA grading scales for future intervention studies. |
|---|
| C02 | 01 | X | | @0 002B17 |
|---|
| C02 | 02 | X | | @0 002B17F |
|---|
| C02 | 03 | X | | @0 002B17G |
|---|
| C03 | 01 | X | FRE | @0 Système nerveux pathologie @5 01 |
|---|
| C03 | 01 | X | ENG | @0 Nervous system diseases @5 01 |
|---|
| C03 | 01 | X | SPA | @0 Sistema nervioso patología @5 01 |
|---|
| C03 | 02 | X | FRE | @0 Atrophie multisystématisée @2 NM @5 02 |
|---|
| C03 | 02 | X | ENG | @0 Multiple system atrophy @2 NM @5 02 |
|---|
| C03 | 02 | X | SPA | @0 Atrofia multisistematizada @2 NM @5 02 |
|---|
| C03 | 03 | X | FRE | @0 Dégénérescence @5 03 |
|---|
| C03 | 03 | X | ENG | @0 Degeneration @5 03 |
|---|
| C03 | 03 | X | SPA | @0 Degeneración @5 03 |
|---|
| C03 | 04 | X | FRE | @0 Histopathologie @5 09 |
|---|
| C03 | 04 | X | ENG | @0 Histopathology @5 09 |
|---|
| C03 | 04 | X | SPA | @0 Histopatología @5 09 |
|---|
| C03 | 05 | X | FRE | @0 Olivopontocérébelleux @5 10 |
|---|
| C03 | 05 | X | ENG | @0 Olivopontocerebellar @5 10 |
|---|
| C03 | 05 | X | SPA | @0 Olivopontocerebeloso @5 10 |
|---|
| N21 | | | | @1 318 |
|---|
| N44 | 01 | | | @1 OTO |
|---|
| N82 | | | | @1 OTO |
|---|
|
|---|
| pR |
| A30 | 01 | 1 | ENG | @1 Atypical Parkinsonian Disorders - From Protein Dysfunction to Therapeutic Intervention. International Meeting @3 Innsbruck AUT @4 2003-02-19 |
|---|
|
|---|
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001D76
Links to Exploration step
Pascal:05-0457530
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Grading of neuropathology in multiple system atrophy : Proposal for a novel scale</title>
<author><name sortKey="Jellinger, Kurt A" sort="Jellinger, Kurt A" uniqKey="Jellinger K" first="Kurt A." last="Jellinger">Kurt A. Jellinger</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Institute of Clinical Neurobiology</s1>
<s2>Vienna</s2>
<s3>AUT</s3>
<sZ>1 aut.</sZ>
</inist:fA14><country>Autriche</country>
</affiliation><author><name sortKey="Seppi, Klaus" sort="Seppi, Klaus" uniqKey="Seppi K" first="Klaus" last="Seppi">Klaus Seppi</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Neurology, University of Innsbruck School of Medicine</s1>
<s2>Innsbruck</s2>
<s3>AUT</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14><country>Autriche</country>
</affiliation><author><name sortKey="Wenning, Gregor K" sort="Wenning, Gregor K" uniqKey="Wenning G" first="Gregor K." last="Wenning">Gregor K. Wenning</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Neurology, University of Innsbruck School of Medicine</s1>
<s2>Innsbruck</s2>
<s3>AUT</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14><country>Autriche</country>
</affiliation><publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">05-0457530</idno>
<date when="2005">2005</date>
<idno type="stanalyst">PASCAL 05-0457530 INIST</idno>
<idno type="RBID">Pascal:05-0457530</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001D76</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000F45</idno>
</publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Grading of neuropathology in multiple system atrophy : Proposal for a novel scale</title>
<author><name sortKey="Jellinger, Kurt A" sort="Jellinger, Kurt A" uniqKey="Jellinger K" first="Kurt A." last="Jellinger">Kurt A. Jellinger</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Institute of Clinical Neurobiology</s1>
<s2>Vienna</s2>
<s3>AUT</s3>
<sZ>1 aut.</sZ>
</inist:fA14><country>Autriche</country>
</affiliation><author><name sortKey="Seppi, Klaus" sort="Seppi, Klaus" uniqKey="Seppi K" first="Klaus" last="Seppi">Klaus Seppi</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Neurology, University of Innsbruck School of Medicine</s1>
<s2>Innsbruck</s2>
<s3>AUT</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14><country>Autriche</country>
</affiliation><author><name sortKey="Wenning, Gregor K" sort="Wenning, Gregor K" uniqKey="Wenning G" first="Gregor K." last="Wenning">Gregor K. Wenning</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Neurology, University of Innsbruck School of Medicine</s1>
<s2>Innsbruck</s2>
<s3>AUT</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14><country>Autriche</country>
</affiliation><series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2005">2005</date>
</imprint><seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Degeneration</term>
<term>Histopathology</term>
<term>Multiple system atrophy</term>
<term>Nervous system diseases</term>
<term>Olivopontocerebellar</term>
</keywords><keywords scheme="Pascal" xml:lang="fr"><term>Système nerveux pathologie</term>
<term>Atrophie multisystématisée</term>
<term>Dégénérescence</term>
<term>Histopathologie</term>
<term>Olivopontocérébelleux</term>
</keywords><front><div type="abstract" xml:lang="en">Multiple system atrophy (MSA), a sporadic progressive synucleinopathy of advanced age, is separated into two clinic opathological subtypes: MSA-P (striatonigral degeneration [SND]) with predominant parkinsonian features and MSA-C (olivopontocerebellar atrophy [OPCA]) with predominant cerebellar ataxia. We propose a novel morphological grading system for both subtypes to compare lesion intensities and their possible clinical validity. Forty-two autopsy cases of MSA were separated into four grades (SND 0-III and OPCA 0-III) based on semiquantitative assessment of neuronal loss, astrogliosis, and presence of α-synuclein-positive glial cytoplasmic inclusions (GCI) in striatum, globus pallidus, substantia nigra, pontine basis, cerebellum, and inferior olives. Whereas a recent grading system restricted to SND reflected disease progression and dopa-responsiveness, there was considerable variation in the morphological combination between SND and OPCA, with only around half the cases with OPCA II (moderate) and III (severe) showing comparable grades of both types, whereas OPCA 0 and I (no or little degeneration) was combined with all grades of SND. Twenty-two cases showing OPCA 0 + SND II (n = 3), OPCA I + SND I-II (n = 11), and OPCA I + SND III (n = 8) were classified as pure or predominant SND, consistent with MSA-P. Twenty cases showing OPCA II + SND II/III (n = 7) and OPCA III + SND III (n = 13) were classified as predominant OPCA, consistent with MSA-C. In MSA-P, the mean age of onset was higher than it was in MSA-C (55.1 vs. 50.5 years), but the mean duration of illness was shorter in MSA-P (5.3 vs. 6.7 years). Presenting symptoms in MSA-P were mainly parkinsonism, whereas in MSA-C they were mainly gait disorders (14 vs. 1; P < 0.001). Among clinical key symptoms, parkinsonism was more frequent than were cerebellar signs in MSA-P; in MSA-C it was the reverse (P < 0.01), whereas other symptoms (autonomic/ urinary failure) showed no differences. Parkinsonism was infrequent in MSA-C even when OPCA was associated with SND, suggesting a masking effect by cerebellar system involvement. High terminal Hoehn and Yahr stages were more frequent in MSA-P (P < 0.01), some with good-to-moderate initial levodopa (L-dopa) response. Although the proposed morphological grading of both MSA-P and -C correlates well with initial symptoms and clinical key features of both types, further prospective studies are required to validate the clinical utility of the proposed MSA grading scales for future intervention studies.</div>
</front><inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01><fA03 i2="1"><s0>Mov. disord.</s0>
</fA03><fA06><s3>SUP12</s3>
</fA06><fA08 i1="01" i2="1" l="ENG"><s1>Grading of neuropathology in multiple system atrophy : Proposal for a novel scale</s1>
</fA08><fA09 i1="01" i2="1" l="ENG"><s1>Atypical Parkinsonian Disorders</s1>
</fA09><fA11 i1="01" i2="1"><s1>JELLINGER (Kurt A.)</s1>
</fA11><fA11 i1="02" i2="1"><s1>SEPPI (Klaus)</s1>
</fA11><fA11 i1="03" i2="1"><s1>WENNING (Gregor K.)</s1>
</fA11><fA12 i1="01" i2="1"><s1>POEWE (Werner)</s1>
<s9>ed.</s9>
</fA12><fA12 i1="02" i2="1"><s1>WENNING (Gregor K.)</s1>
<s9>ed.</s9>
</fA12><fA14 i1="01"><s1>Institute of Clinical Neurobiology</s1>
<s2>Vienna</s2>
<s3>AUT</s3>
<sZ>1 aut.</sZ>
</fA14><fA14 i1="02"><s1>Department of Neurology, University of Innsbruck School of Medicine</s1>
<s2>Innsbruck</s2>
<s3>AUT</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</fA14><fA15 i1="01"><s1>Department of Neurology, Medical University Innsbruck</s1>
<s2>Innsbruck</s2>
<s3>AUT</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</fA15><fA20><s2>S29-S36</s2>
</fA20><fA21><s1>2005</s1>
</fA21><fA23 i1="01"><s0>ENG</s0>
</fA23><fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000132714250050</s5>
</fA43><fA44><s0>0000</s0>
<s1>© 2005 INIST-CNRS. All rights reserved.</s1>
</fA44><fA45><s0>28 ref.</s0>
</fA45><fA47 i1="01" i2="1"><s0>05-0457530</s0>
</fA47><fA60><s1>P</s1>
<s2>C</s2>
</fA60><fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64><fA66 i1="01"><s0>USA</s0>
</fA66><fC01 i1="01" l="ENG"><s0>Multiple system atrophy (MSA), a sporadic progressive synucleinopathy of advanced age, is separated into two clinic opathological subtypes: MSA-P (striatonigral degeneration [SND]) with predominant parkinsonian features and MSA-C (olivopontocerebellar atrophy [OPCA]) with predominant cerebellar ataxia. We propose a novel morphological grading system for both subtypes to compare lesion intensities and their possible clinical validity. Forty-two autopsy cases of MSA were separated into four grades (SND 0-III and OPCA 0-III) based on semiquantitative assessment of neuronal loss, astrogliosis, and presence of α-synuclein-positive glial cytoplasmic inclusions (GCI) in striatum, globus pallidus, substantia nigra, pontine basis, cerebellum, and inferior olives. Whereas a recent grading system restricted to SND reflected disease progression and dopa-responsiveness, there was considerable variation in the morphological combination between SND and OPCA, with only around half the cases with OPCA II (moderate) and III (severe) showing comparable grades of both types, whereas OPCA 0 and I (no or little degeneration) was combined with all grades of SND. Twenty-two cases showing OPCA 0 + SND II (n = 3), OPCA I + SND I-II (n = 11), and OPCA I + SND III (n = 8) were classified as pure or predominant SND, consistent with MSA-P. Twenty cases showing OPCA II + SND II/III (n = 7) and OPCA III + SND III (n = 13) were classified as predominant OPCA, consistent with MSA-C. In MSA-P, the mean age of onset was higher than it was in MSA-C (55.1 vs. 50.5 years), but the mean duration of illness was shorter in MSA-P (5.3 vs. 6.7 years). Presenting symptoms in MSA-P were mainly parkinsonism, whereas in MSA-C they were mainly gait disorders (14 vs. 1; P < 0.001). Among clinical key symptoms, parkinsonism was more frequent than were cerebellar signs in MSA-P; in MSA-C it was the reverse (P < 0.01), whereas other symptoms (autonomic/ urinary failure) showed no differences. Parkinsonism was infrequent in MSA-C even when OPCA was associated with SND, suggesting a masking effect by cerebellar system involvement. High terminal Hoehn and Yahr stages were more frequent in MSA-P (P < 0.01), some with good-to-moderate initial levodopa (L-dopa) response. Although the proposed morphological grading of both MSA-P and -C correlates well with initial symptoms and clinical key features of both types, further prospective studies are required to validate the clinical utility of the proposed MSA grading scales for future intervention studies.</s0>
</fC01><fC02 i1="01" i2="X"><s0>002B17</s0>
</fC02><fC02 i1="02" i2="X"><s0>002B17F</s0>
</fC02><fC02 i1="03" i2="X"><s0>002B17G</s0>
</fC02><fC03 i1="01" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>01</s5>
</fC03><fC03 i1="01" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>01</s5>
</fC03><fC03 i1="01" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>01</s5>
</fC03><fC03 i1="02" i2="X" l="FRE"><s0>Atrophie multisystématisée</s0>
<s2>NM</s2>
<s5>02</s5>
</fC03><fC03 i1="02" i2="X" l="ENG"><s0>Multiple system atrophy</s0>
<s2>NM</s2>
<s5>02</s5>
</fC03><fC03 i1="02" i2="X" l="SPA"><s0>Atrofia multisistematizada</s0>
<s2>NM</s2>
<s5>02</s5>
</fC03><fC03 i1="03" i2="X" l="FRE"><s0>Dégénérescence</s0>
<s5>03</s5>
</fC03><fC03 i1="03" i2="X" l="ENG"><s0>Degeneration</s0>
<s5>03</s5>
</fC03><fC03 i1="03" i2="X" l="SPA"><s0>Degeneración</s0>
<s5>03</s5>
</fC03><fC03 i1="04" i2="X" l="FRE"><s0>Histopathologie</s0>
<s5>09</s5>
</fC03><fC03 i1="04" i2="X" l="ENG"><s0>Histopathology</s0>
<s5>09</s5>
</fC03><fC03 i1="04" i2="X" l="SPA"><s0>Histopatología</s0>
<s5>09</s5>
</fC03><fC03 i1="05" i2="X" l="FRE"><s0>Olivopontocérébelleux</s0>
<s5>10</s5>
</fC03><fC03 i1="05" i2="X" l="ENG"><s0>Olivopontocerebellar</s0>
<s5>10</s5>
</fC03><fC03 i1="05" i2="X" l="SPA"><s0>Olivopontocerebeloso</s0>
<s5>10</s5>
</fC03><fN21><s1>318</s1>
</fN21><fN44 i1="01"><s1>OTO</s1>
</fN44><fN82><s1>OTO</s1>
</fN82><pR><fA30 i1="01" i2="1" l="ENG"><s1>Atypical Parkinsonian Disorders - From Protein Dysfunction to Therapeutic Intervention. International Meeting</s1>
<s3>Innsbruck AUT</s3>
<s4>2003-02-19</s4>
</fA30>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000F45 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 000F45 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= PascalFrancis
|étape= Curation
|type= RBID
|clé= Pascal:05-0457530
|texte= Grading of neuropathology in multiple system atrophy : Proposal for a novel scale
}}
| This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024 |  |
